高级搜索
吉西他滨联合顺铂治疗老年晚期恶性肿瘤的临床观察[J]. 肿瘤防治研究, 2008, 35(05): 355-357. DOI: 10.3971/j.issn.1000-8578.2835
引用本文: 吉西他滨联合顺铂治疗老年晚期恶性肿瘤的临床观察[J]. 肿瘤防治研究, 2008, 35(05): 355-357. DOI: 10.3971/j.issn.1000-8578.2835
Gemcitabine plus Cisplatin Combination in Treatment of Elderly Patients with Advanced Cancer[J]. Cancer Research on Prevention and Treatment, 2008, 35(05): 355-357. DOI: 10.3971/j.issn.1000-8578.2835
Citation: Gemcitabine plus Cisplatin Combination in Treatment of Elderly Patients with Advanced Cancer[J]. Cancer Research on Prevention and Treatment, 2008, 35(05): 355-357. DOI: 10.3971/j.issn.1000-8578.2835

吉西他滨联合顺铂治疗老年晚期恶性肿瘤的临床观察

Gemcitabine plus Cisplatin Combination in Treatment of Elderly Patients with Advanced Cancer

  • 摘要: 目的观察吉西他滨联合顺铂治疗老年晚期恶性肿瘤的临床疗效,毒副反应,临床收益反应。方法吉西他滨800mg/m2静脉点滴第1,8,15天;顺铂30mg/m2静脉点滴第2~4天,28天为1周期,完成2周期后评价疗效。至少治疗2个周期。结果64例均可评价,总有效率为46.9%,其中非小细胞肺癌28例,有效率为46.4%,胰腺癌18例,有效率为44.4%,乳腺癌18例,有效率为50%,中位生存期为11个月,疾病进展时间为6.2个月,1年生存率及2年生存率分别为43.8%和23.4%。疾病相关症状显著改善,体力状态改善率62.5%,主要不良反应为骨髓抑制及消化道反应。无治疗相关性死亡。结论吉西他滨联合顺铂化疗治疗老年晚期恶性肿瘤近期有效率较高。毒副反应轻,耐受性好,并可以改善疾病相关症状,值得临床应用。

     

    Abstract: Objective  To evaluate the efficacy and toxicity of a combination of gemcitabine and cisplatin in elderly patient s with advanced cancer, the clinical benefitial response. Methods  Gem 800 mg/ m2 ivdrop d1, 8, 15 ;DDP 30 mg/ m2 iv drop d2~4, each cycle lasted for 28 days, at least for 2 cycles. Results  Sixty four patient s were evaluated with 46. 9 %, twenty2eight patient s of NSCLC were evaluated with 46. 4 %, eighteen patient s of pancreatic cancer were evaluated with 44. 4 %, eighteen patient s of breast cancer were evaluated with 50. 0 %. Median survival time and TTP was 11 months and 6. 2 months, the curative effect included easement of pain, obviously improvement of general state, better quality of exist2 ence and increased KPS score. The main adverse effect s were bone marrow depression, nausea, vomitting and so on. There was no t reatment related death. Conclusion  The elderly patient s with advanced cancer t reated with GP regimen may obtain high remission rate and low toxicity and better tolerated alternative and represent s an option for the t reatment of the elderly patient s with advanced cancer.

     

/

返回文章
返回